Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study

Int J Hematol. 2023 Feb;117(2):206-215. doi: 10.1007/s12185-022-03473-y. Epub 2022 Oct 29.

Abstract

Adult T cell leukemia-lymphoma (ATL) is clinically heterogeneous and is classified into four subtypes: acute, lymphoma, chronic, and smoldering. Recently, a new prognostic index based on the value of soluble interleukin-2 receptor, denoted the "iATL-PI," has been proposed for patients with smoldering and chronic ATL. To evaluate the effectiveness of the iATL-PI, we re-analyzed our previously published data on 176 patients with smoldering or chronic ATL (76 smoldering, 100 chronic) diagnosed between 2010 and 2011, as well data from the subsequent follow-up study on prognosis between 2016 and 2017. The proportions for the low-, intermediate-, and high-risk iATL-PI groups at the time of ATL diagnosis were 44.7%, 48.7%, and 5% for smoldering ATL; 6.3%, 71.9%, and 21.9% for favorable chronic ATL; and 5.9%, 27.9%, and 66.2% for unfavorable chronic ATL, respectively. The survival of patients with smoldering or chronic ATL as a whole was significantly stratified according to the three iATL-PI groups. Most patients with unfavorable chronic ATL in the low iATL-PI risk group had indolent clinical courses. Our results showed that iATL may become a useful tool to predict the prognosis of smoldering and chronic ATL, which have diverse clinical courses.

Keywords: ATL; Favorable and unfavorable chronic type; Soluble interleukin-2 receptor; iATL-PI.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Follow-Up Studies
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell* / diagnosis
  • Leukemia-Lymphoma, Adult T-Cell* / pathology
  • Leukemia-Lymphoma, Adult T-Cell* / therapy
  • Lymphoma*
  • Prognosis
  • Receptors, Interleukin-2

Substances

  • Receptors, Interleukin-2